# RNN 1st Gen Model Eli Lilly and Company Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
May 3, 2018
Deal entry on
May 3, 2018
2.27%Expected margin
68.49% successful of 73 deals
$ 238.98 Last close price
at 18-oct-2021


Model's trade recommendations 1.61% Return for period

0.65% Annual return

$85.56B Market Cap

β 0.26  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.61%
52wk return 0.36%
52wk Range
Sortino ratio 0.09
Sharpe ratio 0.08
Norm. RMSE 0.59%
Downside risk 8.36%
Volatility 0.00%
  • 2.25 (2.85%) Div (Yield)
  • BUY Analysts consensus recommendation

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Eli Lilly and Company (LLY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for LLY model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for LLY.

Model is being retrained on a daily basis.

Float 1084M
P/E 16.99
Shares Outstanding 1085M
% Held by Insiders 0.11%
% Held by Institutions 77.67%
EPS (last reported FY) $4.28
EPS (last reported Q) $1.34
EPS, estimated (last reported Q) $1.13
Total revenues $23 B
Net income $-0 B